Literature DB >> 30536956

Liberal versus conservative fluid therapy in adults and children with sepsis or septic shock.

Danyang Li1, Xueyang Li, Wei Cui, Huahao Shen, Hong Zhu, Yi Xia.   

Abstract

BACKGROUND: Sepsis and septic shock are potentially life-threatening complications of infection that are associated with high morbidity and mortality in adults and children. Fluid therapy is regarded as a crucial intervention during initial treatment of sepsis. Whether conservative or liberal fluid therapy can improve clinical outcomes in patients with sepsis and septic shock remains unclear.
OBJECTIVES: To determine whether liberal versus conservative fluid therapy improves clinical outcomes in adults and children with initial sepsis and septic shock. SEARCH
METHODS: We searched CENTRAL, MEDLINE, Embase, intensive and critical care conference abstracts, and ongoing clinical trials on 16 January 2018, and we contacted study authors to try to identify additional studies. SELECTION CRITERIA: We planned to include all randomized controlled trials (RCTs), quasi-RCTs, and cluster RCTs comparing liberal fluid therapy versus conservative fluid therapy for adults and children with sepsis or septic shock. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. We assessed risk of bias of all included trials by using the Cochrane risk of bias tool. When appropriate, we calculated risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous outcomes, and mean differences (MDs) and 95% CIs for continuous outcomes. Our primary outcomes were all-cause mortality in hospital and at follow-up. Secondary outcomes included adverse events (organ dysfunction, allergic reaction, and neurological sequelae). We used GRADE to assess the quality of evidence for each outcome. MAIN
RESULTS: We identified no adult studies that met our selection criteria.This review included three paediatric RCTs (N = 3402), but we were able to extract data from only two of the three trials (n = 3288). These trials were conducted in India (two studies) and Africa. Participants were children from one month to 12 years old with sepsis or septic shock. All three included trials investigated liberal versus conservative fluid therapy, although definitions of liberal and conservative fluid therapy varied slightly across included studies. Results of the two trials included in the analyses show that liberal fluid therapy may increase risk of in-hospital mortality by 38% (2 studies; N = 3288; RR 1.38, 95% CI 1.07 to 1.77; number needed to treat for an additional harmful outcome (NNTH) = 34; moderate-quality evidence) and may increase risk of mortality at follow-up (at four weeks) by 39% (1 study; N = 3141; RR 1.39, 95% CI 1.11 to 1.74; NNTH = 29; high-quality evidence). The third study reported inconclusive results for in-hospital mortality (very low-quality evidence).We are uncertain whether there is a difference in adverse events between liberal and conservative fluid therapy because the single-study results are imprecise (organ dysfunction - hepatomegaly: RR 0.95, 95% CI 0.60 to 1.50; n = 147; low-quality evidence; organ dysfunction - need for ventilation: RR 1.17, 95% CI 0.83 to 1.65; n = 147; low-quality evidence; allergic reaction: RR 1.74, 95% CI 0.36 to 8.37; n = 3141; low-quality evidence; neurological sequelae: RR 1.03, 95% CI 0.61 to 1.75; n = 2983; low-quality evidence). Results are also uncertain for other adverse events such as desaturation, tracheal intubation, increased intracranial pressure, and severe hypertension. AUTHORS'
CONCLUSIONS: No studies compared liberal versus conservative fluid therapy in adults. Low- to high-quality evidence indicates that liberal fluid therapy might increase mortality among children with sepsis or septic shock in hospital and at four-week follow-up. It is uncertain whether there are any differences in adverse events between liberal and conservative fluid therapy because the evidence is of low quality. Trials including adults, patients in other settings, and patients with a broader spectrum of pathogens are needed. Once published and assessed, three ongoing studies may alter the conclusions of this review.

Entities:  

Mesh:

Year:  2018        PMID: 30536956      PMCID: PMC6517253          DOI: 10.1002/14651858.CD010593.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  44 in total

1.  The FEAST trial of fluid bolus in African children with severe infection.

Authors:  Gabriele Rossi
Journal:  Lancet       Date:  2012-02-18       Impact factor: 79.321

2.  Making sense of odds and odds ratios.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Obstet Gynecol       Date:  2008-02       Impact factor: 7.661

3.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

4.  Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria.

Authors:  Samuel O Akech; Julie Jemutai; Molline Timbwa; Esther Kivaya; Mwanamvua Boga; Greg Fegan; Kathryn Maitland
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

Review 5.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 6.  Vasopressors for hypotensive shock.

Authors:  Gunnar Gamper; Christof Havel; Jasmin Arrich; Heidrun Losert; Nathan Leon Pace; Marcus Müllner; Harald Herkner
Journal:  Cochrane Database Syst Rev       Date:  2016-02-15

7.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

8.  Fluid Resuscitation with 5% albumin versus Normal Saline in Early Septic Shock: a pilot randomized, controlled trial.

Authors:  Lauralyn A McIntyre; Dean A Fergusson; Deborah J Cook; Brian H Rowe; Sean M Bagshaw; Dave Easton; Marcel Emond; Simon Finfer; Alison Fox-Robichaud; Claude Gaudert; Robert Green; Paul Hebert; John Marshall; Nigel Rankin; Ian Stiell; Alan Tinmouth; Joe Pagliarello; Alexis F Turgeon; Andrew Worster; Ryan Zarychanski
Journal:  J Crit Care       Date:  2011-12-15       Impact factor: 3.425

9.  Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial.

Authors:  Lauralyn A McIntyre; Dean Fergusson; Deborah J Cook; Nigel Rankin; Vinay Dhingra; John Granton; Sheldon Magder; Ian Stiell; Monica Taljaard; Paul C Hebert
Journal:  Can J Anaesth       Date:  2008-12       Impact factor: 5.063

10.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.

Authors:  Carolin Fleischmann; André Scherag; Neill K J Adhikari; Christiane S Hartog; Thomas Tsaganos; Peter Schlattmann; Derek C Angus; Konrad Reinhart
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

View more
  6 in total

Review 1.  Pediatric Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

Authors:  Ian K Maconochie; Richard Aickin; Mary Fran Hazinski; Dianne L Atkins; Robert Bingham; Thomaz Bittencourt Couto; Anne-Marie Guerguerian; Vinay M Nadkarni; Kee-Chong Ng; Gabrielle A Nuthall; Gene Y K Ong; Amelia G Reis; Stephen M Schexnayder; Barnaby R Scholefield; Janice A Tijssen; Jerry P Nolan; Peter T Morley; Patrick Van de Voorde; Arno L Zaritsky; Allan R de Caen
Journal:  Resuscitation       Date:  2020-10-21       Impact factor: 5.262

Review 2.  Sepsis in paediatrics.

Authors:  H D O'Reilly; K Menon
Journal:  BJA Educ       Date:  2020-12-07

3.  Liberal versus conservative fluid therapy in adults and children with sepsis or septic shock.

Authors:  Danyang Li; Xueyang Li; Wei Cui; Huahao Shen; Hong Zhu; Yi Xia
Journal:  Cochrane Database Syst Rev       Date:  2018-12-10

4.  Lung Ultrasound Assisted Comparison of Volume Effects of Fluid Replacement Regimens in Pediatric Patients Undergoing Penile Hypospadias Repair: A Randomized Controlled Trial.

Authors:  Mohamed Elsonbaty; Sherif Abdullah; Ahmed Elsonbaty
Journal:  Anesth Pain Med       Date:  2021-07-03

5.  Prospective Cohort Study on Cumulative Fluid Balance and Outcome in Critically Ill Children Using a Restrictive Fluid Protocol.

Authors:  Ramachandran Rameshkumar; Muthu Chidambaram; Singanamalla Bhanudeep; Kandamaran Krishnamurthy; Abraar Sheriff; Tamil Selvan; Subramanian Mahadevan
Journal:  Indian J Pediatr       Date:  2021-06-09       Impact factor: 1.967

6.  Controversies in the application of corticosteroids for pediatric septic shock treatment: a preferred reporting items for systematic reviews and meta-analysis-compliant updated meta-analysis.

Authors:  Jing Yang; Shaobo Sun
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.